Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
Retrieved on:
Thursday, October 21, 2021
Medical Supplies, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Neurology, Nephrology, Solubility, Nucleotide, Invention, Failure, Merck, COVID-19 vaccine, Twitter, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, NASDAQ, Drug discovery, Baxter International, Gilead Sciences, Jazz Pharmaceuticals, Roche, Exercise, Amgen, Sanofi, Kidney, Marketing, CEO, Trial of the century, COVID-19, Psychiatry, Program, Pharmacokinetics, News, API, Conditional sentence, Pediatrics, GSK, Risk, China Resources, Toxicity, Janssen, Pharmaceutical industry, Fine chemical, CR Double-Crane Pharmaceutical, Ligand, CR DOUBLE-CRANE PHARMACEUTICAL, LIGAND
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligands BEPro technology.
Key Points:
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligands BEPro technology.
- BEPro is a proprietary prodrug technology that is specifically applicable to nucleotides and nucleotide analogs for the development of compounds with improved product profiles.
- Ligand has filed multiple patents globally on the BEPro technology and potential antiviral compounds.
- Ligands OmniAb technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies.